Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Appendix
Innovation: Clinical trials
References
Abbreviations
Confident in future growth driven by our strength and depth in
cardio-renal, immunology, neuroscience...
Selected assets, nearly all with exclusivity into 2030+
New for Q1
Cardio-Renal
Immunology
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Asset
Indication
Peak Sales Next Milestone/ Status
Submission
Leqvio®
CVRR-LDLC
Ph3 ORION-4 and VICTORION-2- 2026+
PREVENT ongoing
CosentyxⓇ
HS
Ph3 SUNRISE, SUNSHINE
positive readout
2022
Primary prevention initiation
Iptacopan1 IgAN
Ph3 APPLAUSE-IgAN ongoing
20232
C3G
iMN
Pelacarsen
CVRR-Lp(a)
Ph3 APPEAR-C3G ongoing
2023
GCA
Lupus Nephritis
Lichen Planus
Ph3 ongoing
2024
Ph3 SELUNE ongoing
2026+
Ph2b PRELUDE readout in 2022
2025
Ph2b ongoing
Ph3 Lp(a)HORIZON ongoing
2026+
2025
Ligelizumab
Remibrutinib1
Food allergy³
Ph3 ongoing
2025
CSU
Ph3 REMIX-1 and -2 ongoing
2024
Neuroscience
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
lanalumab
Other indications being explored
Sjögren's
SLE
Ph3 start in 2022
2026+
Ph2a ongoing
2026+
ZolgensmaⓇ SMA IT
Ph3 STEER initiated
2025
Autoimmune hepatitis
Ph2b ongoing
2026+
Branaplam
Huntington's disease
Ph2b VIBRANT-HD ongoing
2026+
Lupus Nephritis
Ph3 start in 2022
2026+
Iscalimab
Sjögren's
Ph2b ongoing
2026+
Remibrutinib¹ Multiple sclerosis
Ph3 REMODEL-1 and -2 ongoing 2025
Liver Tx
Ph2b ongoing
2026+
DLX313
(UCB0599)
Parkinson's disease
Ph2 ongoing
2026+
HS
Ph2a ongoing
2026+
Unprobabilized peak sales (USD): ⚫ <1bn •⚫ 1-2bn
... >2bn
'Wild Cards'
LNA043 (osteoarthritis: Ph2 ongoing), ecleralimab (CSJ117 asthma: Ph2b ongoing, COPD: Ph2 ongoing),
QBW251 (COPD: Ph2b readout imminent), SAF312 (COSP: Ph2b ongoing), UNR844 (presbyopia: Ph2b readout H2 2022)
1. Peak sales potential based on all studied indications. 2. Based on 9 months UPCR readout (US accelerated approval). 3. Food Allergy indication falls within the Respiratory & Allergy therapeutic area.
33 Investor Relations | Q1 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation